Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00973284
Other study ID # LV01-103
Secondary ID U1111-1176-0535
Status Completed
Phase Phase 1/Phase 2
First received September 8, 2009
Last updated August 4, 2017
Start date August 4, 2009
Est. completion date August 18, 2010

Study information

Verified date August 2017
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to evaluate the efficacy of the Norwalk virus-like particle (VLP) vaccine as determined by the illness rate of viral acute gastroenteritis (AGE) during the inpatient stay.


Description:

The drug being tested in this study is called intranasal Norwalk virus-like particle (VLP) vaccine. Norwalk VLP vaccine is being tested to prevent viral acute gastroenteritis (AGE). This study will look at the illness rate of AGE in people who are administered the Norwalk VLP vaccine.

The study enrolled 98 patients and was conducted in 2 stages: the Vaccination Stage and the Challenge Stage. In the Vaccination Stage participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups—which remained undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

- Norwalk VLP Vaccine (100 µg VLP) intranasally

- Placebo (dummy inactive powder) - this is a powder that looks like the study drug but has no active ingredient During the Challenge Stage participants were administered live Norwalk virus and were monitored for AGE.

This multi-center trial was conducted in the United States. The overall time to participate in this study was up to 29 weeks Participants made multiple visits to the clinic and were contacted by telephone 6 months after last dose of study drug for a follow-up assessment.


Recruitment information / eligibility

Status Completed
Enrollment 98
Est. completion date August 18, 2010
Est. primary completion date April 7, 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. Signed informed consents.

2. Age 18 - 50 years, inclusive.

3. Good general health as determined by a screening evaluation within 45 days of randomization.

4. Expressed interest, availability, and understanding to fulfill the study requirements including measures to prevent Norwalk virus contamination of the environment and spread of infection and illness to the community. The prospective subjects must pass (> 75 % correct answers) a written examination on all aspects of the study before enrollment. (Appendix D)

5. Available to return for follow-up visits following discharge from the inpatient unit and deliver stool specimens to the investigator promptly.

6. Female subjects must be of non-childbearing potential, or if of childbearing potential (as determined by the investigator) must be practicing abstinence or using an effective licensed method of birth control (e.g. oral contraceptives; diaphragm or condom in combination with contraceptive jelly, cream, or foam; intrauterine contraceptive device, or Depo-Provera; skin patch; vaginal ring or cervical cap) for 30 days prior to vaccination and must agree to continue such precautions during the study and for 60 days after the Challenge visit. Male subjects must agree not to father a child during the study and for 60 days after the Challenge visit.

7. Demonstrated to be H type-1 antigen secretor positive (by saliva test). [This saliva test may be done outside of the 45 day window and does not need to be repeated.]

8. Agrees not to participate in another clinical trial with an investigational product for the entire duration of the study (six months after the last dose of study vaccine or placebo i.e. 201 days).

Exclusion Criteria:

1. Living with or having daily contact with children age 5 years or less or a woman known to be pregnant. This includes significant contact at home, school, day-care, or equivalent facilities.

2. Nursing mother.

3. Living with or having daily contact with childcare workers.

4. Living with or having daily contact with elderly persons aged 70 years or more, or infirmed, diapered individuals, persons with disabilities or incontinent persons. This includes work or visits to nursing homes and day-care or equivalent facilities.

5. Evidence of recent (within 2 months) or of current nonbacterial gastroenteritis suggestive of Norwalk virus infection [vomiting or unformed or watery stools ( > 2 during a 24 hour period)].

6. Any gastroenteritis within the past 2 weeks.

7. History of chronic functional dyspepsia, chronic gastroesophageal reflux disease, peptic ulcer disease, gastrointestinal hemorrhage, gall bladder disease, inflammatory bowel disease, irritable bowel syndrome, frequent diarrhea, chronic constipation, or diverticulitis anytime during the subject's lifetime.

8. Regular use of medication other than oral contraceptive agents, anti-hypertensives, anti-depressants, vitamins and minerals.

9. History of any of the following medical illnesses:

- Chronic rhinitis, runny nose, sneezing (including seasonal allergies)

- Clinically significant nose bleed within the prior 12 months

- Diabetes

- Cancer (malignancies other than a resolved skin lesion)

- Heart disease (hospitalization for a heart attack, arrhythmia, or syncope)

- Unconsciousness (other than a single brief "concussion")

- Seizures (other than febrile seizures as a child <5 years old)

- Asthma requiring treatment with inhaler or medication in the prior 2 years

- Neuro-inflammatory disease

- Autoimmune disease

- Eating disorder

- Chronic headaches associated with vomiting

- Chronic vomiting syndrome

10. Any current illness requiring daily medication other than vitamins, minerals, birth control, anti-depressants or anti-hypertensives.

11. Blood Type B or AB. [This blood test may be done outside of the 45 day window and does not need to be repeated.]

12. Allergies or hypersensitivity to chitosan, shrimp, other shellfish or any component of the vaccine or placebo.

13. History of nasal surgery of any type (including tonsillectomy or adenoidectomy).

14. Any clinically significant abnormality detected on physical examination, including:

- Murmur (other than a functional murmur)

- Focal neurological abnormality

- Hepatosplenomegaly

- Lymphadenopathy

- Jaundice

15. Hypertension defined as BP > 150/90 mm Hg on two separate measurements. Chronic stable well-controlled hypertension on medications is allowed.

16. History of more than 3 hospitalizations for invasive bacterial infections (pneumonia, meningitis), acute or chronic dermatitis (e.g. eczema, seborrhea, psoriasis) or collagen vascular disease [e.g. systemic lupus erythematosus (SLE) or dermatomyositis].

17. Presence of other serious chronic illness (i.e. malignancy other than a resolved skin lesion).

18. Positive stool/fecal culture for bacterial pathogens (salmonella, campylobacter, E. coli 0157:H7, and shigella) or positive stool/fecal screen for ova and parasites.

19. Employment in the food service industry, such as restaurants, or cafeteria facilities. Specifically, this will include persons whose employment requires food processing in the 4 weeks following challenge.

20. Health-care workers with patient contact expected in the 4 weeks following challenge.

21. Expected contact (through employment or at home) with immunocompromised persons (HIV-positive, receiving immunosuppressive medications such as oral steroids, anti-neoplastic agents) in the 4 weeks following challenge.

22. Employment as an airline flight attendant, scheduled to work in the 4 weeks following challenge.

23. Persons planning on taking a cruise in the 4 weeks following challenge.

24. Persons who have consumed or plan to consume raw shellfish (e.g. oysters) within 7 days prior to enrollment or throughout the study.

25. Any of the following lab abnormalities:

- Absolute neutrophil count (ANC) or total white blood cell (WBC) outside the normal range (may be repeated once if outside this limit)

- Hemoglobin outside the normal range (may be repeated once if outside this limit)

- Platelet count outside the normal range (may be repeated once if outside this limit)

- Electrolytes, blood urea nitrogen (BUN) and/or creatinine outside the normal range (may be repeated once if outside this limit)

- Glucose > upper limit of normal (ULN) (may be repeated once if outside this limit). Fasting glucose is not required.

- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, bilirubin (total and indirect) or gamma glutamyl transferase (GGT) outside the normal range (may be repeated once if outside this limit)

- Positive serology for hepatitis C or human immunodeficiency virus (HIV) antibody or hepatitis B surface antigen or rapid plasma reagin (RPR)

26. For women, positive serum pregnancy test within 14 days or positive urine pregnancy test within 24 hours of randomization.

27. Temperature > 99.7°F orally or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within 3 days of randomization.

28. Previous participation in a study of experimental norovirus infection or vaccines.

29. Study site personnel or their family members.

30. Significant history of psychiatric hospitalization, alcohol abuse, or illicit drug use.

31. Receipt of a licensed live vaccine within 28 days or a licensed inactivated vaccine within 14 days of randomization.

32. Completion of an investigational vaccine or drug study within 28 days of randomization.

33. Other condition that in the clinical judgment of the investigator would jeopardize the safety or rights of a subject participating in the trial, would render the subject unable to comply with the protocol or would interfere with the evaluation of the vaccination stage or the evaluation of the challenge stage.

Study Design


Intervention

Biological:
Norwalk VLP vaccine
Norwalk VLP vaccine dry powder
mannitol and sucrose
Mannitol and sucrose as placebo-matching Norwalk VLP Vaccine dry powder
Norwalk virus
Norwalk virus solution

Locations

Country Name City State
United States SNBL Baltimore Maryland
United States Cincinnati Childrens Hospital Medical Center Cincinnati Ohio
United States Baylor College of Medicine Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants with Viral Acute Gastroenteritis (AGE) Viral AGE was a composite endpoint for the analysis of clinical illness and was defined as meeting one or more definitions of Norwalk Virus Infection and one or more of the definitions of AGE.
Norwalk Virus Infection:
PAN-Immunoglobulin (Ig) Enzyme Linked Immunosorbent Assay (ELISA) for anti-Norwalk Virus Antibody IgM, IgG and IgA, =4-fold rise in titer in serum on Challenge Day 30 compared to Pre-Challenge.
Reverse Transcription Polymerase Chain Reaction (RT-PCR), a single positive post-challenge stool sample.
Norwalk Virus Antigen, a single positive post-challenge stool sample.
Acute Gastroenteritis:
->200 grams of watery feces in 24-hour collection that immediately takes the shape of the container.
Vomiting and watery feces =200 grams on the same or consecutive days.
One vomiting episode plus one of the following symptoms: abdominal cramps or pains, nausea, bloating, loose feces, fever =99.7° Fahrenheit, or myalgia on the same or consecutive days.
7 Days Post-Challenge
Secondary Percentage of Participants with Norwalk Virus Infection Anytime Post Challenge Norwalk Virus Infection was defined as meeting one or more of the following criteria:
Norwalk Virus Antigen, a single positive post-challenge stool sample.
Reverse Transcription Polymerase Chain Reaction (RT-PCR), a single positive post-challenge stool sample.
PAN-Immunoglobulin (Ig) Enzyme Linked Immunosorbent Assay (ELISA) for anti-Norwalk Virus Antibody IgM, IgG and IgA, =4-fold rise in titer in serum on Challenge Day 30 compared to Pre-Challenge.
Up to 30 Days Post-Challenge
Secondary Severity of Viral AGE using the Modified Vesikari Scale Vesikari Scoring System assesses the following symptoms: duration of diarrhea (days), maximum number of diarrheal stools/24 hours, duration of vomiting (days), maximum number of vomiting episodes/24 hours, fever and dehydration. Since the typical inpatient phase was four days in length, the duration of diarrhea scoring was modified to fit this time frame. Modified Vesikari Scale Total Score=17. Higher numbers are worse. Up to 30 Days Post-Challenge
Secondary Duration of Viral AGE Among Challenged Participants Duration of symptoms was determined by a blinded committee review of each participant's symptoms. Participants not ill are included in the calculations with a duration=0. Up to 30 Days Post-Challenge
Secondary Percentage of Participants with Norwalk Virus Antigen Detected in the Stool Stool samples were collected following challenge with Norwalk Virus. A positive test for antigen in post challenge stool sample was considered evidence of Norwalk Virus infection. Days 1 thru 4, 7, 21 and 30 in the Challenge Stage
Secondary Percentage of Participants with Seroconversion in Serum Anti-Norwalk Virus Seroconversion was defined as a 4-fold rise in Pan-Ig ELISA Assay (Combined IgG + IgA + IgM) from Pre-Challenge to Day 30 Post Challenge. Pre-Challenge to 30 Days Post-Challenge
Secondary Percentage of Participants with Norwalk RT-PCR Positive Titer in Stool Anytime Post Challenge RT-PCR was carried out to detect Norwalk Virus RNA in stool samples. A single positive test was taken as evidence of a Norwalk Virus infection. Days 1 thru 4, 7, 21 and 30 in the Challenge Stage
Secondary Percentage of Participants with Any Local Intranasal Symptoms during the Vaccination Stage Local symptoms included nasal stuffiness, nasal itching, sneezing, runny nose/nasal discharge, nasal pain/discomfort, blood tinged nasal mucus and nose bleed. 7 Days Post Dose 1 and 2
Secondary Percentage of Participants with Any Systemic Solicited Symptoms Anytime Post-Challenge Systemic signs or symptoms were defined as headache, fever, nausea, vomiting, abdominal cramps, diarrhea, malaise, and loss of appetite. Up to 21 Days Post-Challenge
Secondary Percentage of Participants with Serious Adverse Events (SAEs) A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. 180 days following the last study vaccination (Up to Day 201)
Secondary Norwalk PAN-Ig Serum-ELISA Geometric Mean Titer (GMT) Pre-Dose 1 and 21 Days Post Dose 1 and Dose 2
Secondary Norwalk PAN-Ig Serum-ELISA Geometric Mean Fold Rise (GMFR) GMFR represents the geometric mean fold rise in antibody at post-dose compared to pre-dose 1. Pre-Dose 1 and 21 Days Post Dose 1 and Dose 2
Secondary Percentage of Participants with Norwalk PAN-Ig Serum-ELISA Seroresponse (4-Fold Rise) 4-Fold Rise represents the percentage of participants with at least a 4-Fold Rise in antibody at Day 21 post dose compared to pre-dose 1. Pre-dose 1 and 21 Days Post Dose 1 and 2
Secondary Norwalk IgG Serum-ELISA GMT Pre-Dose 1 and 21 Days Post Dose 1 and Dose 2
Secondary Norwalk IgG Serum-ELISA GMFR GMFR represents the geometric mean fold rise in antibody at post-dose compared to pre-dose 1. Pre-Dose 1 and 21 Days Post Dose 1 and Dose 2
Secondary Percentage of Participants with Norwalk IgG Serum-ELISA Seroresponse (4-Fold Rise) 4-Fold Rise represents the percentage of participants with at least a 4-Fold Rise in antibody at Day 21 post dose compared to pre-dose 1. Pre-Dose 1 and 21 Days Post Dose 1 and 2
Secondary Norwalk IgA Serum-ELISA GMT Pre-Dose 1 and 21 Days Post Dose 1 and Dose 2
Secondary Norwalk IgA Serum-ELISA GMFR GMFR represents the geometric mean fold rise in antibody at post-dose compared to pre-dose 1. Pre-Dose 1 and 21 Days Post Dose 1 and Dose 2
Secondary Percentage of Participants with Norwalk IgA Serum-ELISA Seroresponse 4-Fold Rise represents the percentage of participants with at least a 4-Fold Rise in antibody at Day 21 post dose compared to pre-dose 1. Pre-Dose 1 and 21 Days Post Dose 1 and 2
See also
  Status Clinical Trial Phase
Completed NCT04682860 - Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide Phase 4
Recruiting NCT03851835 - Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis Phase 3
Completed NCT01577043 - Efficacy of Racecadotril in Acute Watery Diarrhea in Children Phase 4
Completed NCT03234777 - Evaluating a Knowledge Translation Tool for Parents N/A
Not yet recruiting NCT02619201 - Antiemetic Efficacy of Ondansetron Versus Metoclopramide Phase 3
Completed NCT02280759 - Efficacy of Gelatin Tannate in Treatment Acute Gastroenteritis in Children. Phase 1
Completed NCT06090708 - Yogurt Probiotic Bacteria on Relieving Young Children Acute Gastroenteritis N/A
Recruiting NCT05270291 - Infectious Etiology of Vomiting in Children With Presumed Acute Gastroenteritis
Completed NCT02025452 - Novel Diagnostics and Probiotics to Improve Management of Paediatric Acute Gastroenteritis Phase 4
Not yet recruiting NCT06038305 - Prevalence of Anemia and Growth Assessment in Acute Gastroenteritis
Completed NCT02803827 - Optimizing the Management of Acute Diarrhoeal Disease Phase 3
Completed NCT02644200 - Gelatin Tannate as Treatment for Acute Childhood Gastroenteritis Phase 3
Completed NCT02174874 - Ondansetron Oral Versus Orally Disintegrating Tablets (ODT) N/A
Completed NCT03539913 - Efficacy and Safety of Probiotics in the Treatment of Acute Gastroenteritis in Children Phase 4
Recruiting NCT06137014 - Fortified Oral Rehydration Therapy for Pediatric Diarrhea Phase 1/Phase 2
Completed NCT04463355 - Video Discharge Instructions for Pediatric Gastroenteritis in an Emergency Department N/A
Completed NCT04555200 - Continuous Enteral Rehydration by Nasogastric Tube With ORS in Children With Acute Gastroenteritis
Completed NCT02169817 - Evaluation Of Bacillus Clausii In Treatment Of Acute Diarrhea In Latin American Children Phase 4
Unknown status NCT02177799 - Surveillance Study of Acute Gastroenteritis in Hospitalized Children in Rural Area in Lebanon N/A
Completed NCT01886755 - Efficacy of an Oral Rehydration Solution Containing the Probiotic Lactobacillus Reuteri Protectis and Zinc in Infants With Acute Gastroenteritis N/A